Skip to main content

Table 3 Adverse events of grade 3 or higher during anti-PD-1/TA treatment

From: Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma

Event anti-PD-1/TA alone (N = 32) anti-PD-1/TA + SBRT (N = 42)
No. of patients (%)
Any adverse event of grade 3 or 4 21 (65.6) 23 (54.8)
Hypertension 4 (12.5) 5 (11.9)
Fatigue 4 (12.5) 7 (16.7)
Proteinuria 5 (15.6) 1 (2.4)
Diarrhea 3 (9.4) 4 (9.5)
Vomiting 1 (3.1) 1 (2.4)
Colonic obstruction 0 (0) 1 (2.4)
Gastric perforation 1 (3.1) 0 (0)
Hoarseness 1 (3.1) 0 (0)
Hypothyroidism 1 (3.1) 0 (0)
Creatinine increased 2 (4.8) 1 (2.4)
Neutrophil count decreased 1 (3.1) 1 (2.4)
Anemia 3 (9.4) 6 (14.3)
Palmar–plantar erythrodysesthesia syndrome 3 (9.4) 2 (4.8)
Pneumonitis 2 (4.8) 1 (2.4)
Maculopapular rash 1 (3.1) 2 (4.8)